GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » DeferredTaxAndRevenue

Nektar Therapeutics (LTS:0UNL) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Nektar Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

Nektar Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Nektar Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics DeferredTaxAndRevenue Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics Headlines

No Headlines